Xencor Inc
XNCR
查看詳細走勢圖
15.450USD
-0.020-0.13%
收盤 12/24, 13:00（美東）報價延遲15分鐘
1.10B總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-0.13%
5天
-2.22%
1月
-7.71%
6月
+86.82%
今年開始到現在
-32.77%
1年
-36.39%
查看詳細走勢圖
TradingKey Xencor Inc股票評分
單位: USD 更新時間: 2025-12-24操作建議
Xencor Inc當前公司基本面數據相對穩定，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名52/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價28.00。中期看，股價處於上升通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Xencor Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
14
分析師
買入
評級
28.000
目標均價
+58.37%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Xencor Inc亮點
亮點風險
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
利潤高增長
公司淨利潤處於行業前列，最新年度總收入110.49M美元
估值合理
公司最新PE估值-8.96，處於3年歷史合理位
機構減倉
最新機構持股80.43M股，環比減少6.98%
景順投資公司持倉
明星投資者景順投資公司持倉，最新持倉192.79K股
Xencor Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Xencor Inc簡介
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
公司代碼XNCR
公司Xencor Inc
CEODahiyat (Bassil I)
網址https://xencor.com/
常見問題
Xencor Inc(XNCR)的當前股價是多少？
Xencor Inc(XNCR)的當前股價是 15.450。
Xencor Inc 的股票代碼是什麼？
Xencor Inc的股票代碼是XNCR。
Xencor Inc股票的52週最高點是多少？
Xencor Inc股票的52週最高點是24.940。
Xencor Inc股票的52週最低點是多少？
Xencor Inc股票的52週最低點是6.920。
Xencor Inc的市值是多少？
Xencor Inc的市值是1.10B。
Xencor Inc的淨利潤是多少？
Xencor Inc的淨利潤為-232.62M。
現在Xencor Inc(XNCR)的股票是買入、持有還是賣出？
根據分析師評級，Xencor Inc(XNCR)的總體評級為買入，目標價格為28.000。
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是多少
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是-1.725。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
